Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to report first quarter financial results on Thursday, May 6, 2021.

Moderna to Report First Quarter Financial Results on Thursday, May 6, 2021

Moderna, Inc. (MRNA) Management Presents at 20th Annual Needham Healthcare Conference (Transcript)

At its April 14 Vaccines Day, Moderna Inc. (NASDAQ:MRNA) provided evidence that the company has plenty in the tank behind its highly successful Covid-19 shot. The challenge now is to get the products across the finish line.

Moderna's Post-Covid Vaccines Show Promise in Clinical Trials

Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.

Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study

AstraZeneca

Pfizer

The study has major implications given how regulators have reacted to blood-clot concerns.

Pfizer and Moderna Vaccines About as Likely to Trigger Blood Clots as AstraZeneca's, Study Finds

A study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer and Moderna vaccines as they are for the AstraZeneca vaccine that was produced with the university's help. According to CBS News, based on a preprint study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine.

Blood clots as prevalent with Pfizer and Moderna vaccine as with AstraZeneca's: report

Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?

The stock price of Moderna Inc (NASDAQ: MRNA) increased by 6.89%. This is why it happened.

MRNA Stock: 6.89% Increase Explanation

Moderna Inc, looking to boost production of its COVID-19 vaccine, met with Nexus Pharmaceuticals to discuss manufacturing the shot at the company's new plant in Wisconsin, which has the capacity to process and fill 30 million doses a month, sources with knowledge of the matter said.

Moderna discusses COVID-19 vaccine manufacturing with Nexus Pharmaceuticals: sources

The top shareholders of Moderna are Robert S. Langer, Stéphane Bancel, Noubar B.

Top Moderna Shareholders

Jeff Zients said the FDA's recommended pause on J&J's vaccine would not have a "significant impact" on the administration's vaccination program.

White House says U.S. is working to accelerate doses of Pfizer, Moderna Covid vaccines

COVID-19 vaccine shots aren't stopping anytime soon. Moderna announced Americans could start getting booster shots to protect against variant strains later this year.

Americans might start getting a third booster shoot for Moderna vaccines this year (MRNA)

Moderna CEO Stephane Bancel told CNBC the biotech firm hopes to have a booster shot for its Covid vaccine to protect against variants ready by the fall.

Moderna hopes to have Covid booster shot for its vaccine ready by the fall, CEO says

Novavax

Researchers said that a U.K. study of using different Covid-19 vaccines in two-dose inoculations is now expanded to include vaccines made by Moderna Inc (NASDAQ: MRNA) and Novavax Inc (NASDAQ: NVAX), Reuters reports. The trial, known as the Com-Cov study, was first launched in February this year to assess whether giving the first dose of one type of COVID-19 shot and the second dose of another elicits an immune response as good as using two doses of the same vaccine.

UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots

BioNTech SE

Johnson & Johnson

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Which Vaccine Maker Will Win the Fight Against COVID-19?

Just a day before Moderna Inc's (NASDAQ: MRNA) second annual Vaccines Day, the company has posted an update on its COVID-19 Vaccine Program, including a 6-month look at the COVID-19 shot and new preclinical data that suggest its booster candidates stand a chance against new variants. COVID-19 Vaccine Additional Data: An updated review of 900-plus COVID-19 cases from the Phase 3 COVE study confirms the jab is more than 90% effective against all cases and over 95% effective against severe cases.

Moderna's COVID-19 Shot Provides Over 90% Effectiveness Six Months After Second Dose, Boosters Can Potentially Fight Against Variants

DraftKings

JetBlue Airways

Southwest Airlines

Spirit Airlines

Southwest Airlines Co (NYSE: LUV) shares are trading higher by 1% in Wednesday's pre-market session after JPMorgan upgraded the stock from Underperform to Neutral and raised its price target from $44 to $66 per share. Spirit Airlines Incorporated (NYSE: SAVE) shares are trading higher by 2.4% after JPMorgan upgraded the stock from Underweight to Overweight and raised its price target from $31 to $54.

Here's Why Southwest Airlines, Spirit Airlines, JetBlue, DraftKings And Moderna Are Moving

Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride.

Moderna Stock Has Come Off Its Recent Highs — Is It A Buy Right Now?

Moderna Inc. said Wednesday it is hosting its second annual Vaccines Day, offering an update on studies of its mRNA vaccine candidates in a range of illnesses, including flu, HIV and other viruses. The Cambridge, Mass.

Moderna offers update on vaccine program, to launch studies of flu, HIV vaccine candidates in 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces clinical progress from its industry-leading mRNA vaccine franchise and continues investments to accelerate pipeline development.

Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development

The first leg of this trial experimented with replacing the second shot of the AstraZeneca vaccine with a dose of Pfizer's mRNA jab to see it provided a stronger defense against Covid.

U.K. Expands Its Mix-And-Match Covid-19 Vaccine Trial To Include Moderna And Novavax Shots

A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.

Moderna and Novavax added to ‘mix and match' COVID-19 vaccine trial

Moderna Inc. said late Tuesday that its COVID-19 vaccine continued to show "strong efficacy," including greater than 90% efficacy against cases of COVID-19 and greater than 95% against severe cases of COVID-19 in a median six-month follow-up. New preclinical data also showed variant-specific booster vaccine candidates working, the company said.

Moderna says that it COVID-19 vaccine continues to show 'strong efficacy'

Moderna said late Tuesday its updated Covid vaccine generated antibodies against the mutation first discovered in South Africa. The news prodded Moderna stock higher in late action.

Moderna Stock Rises After New Covid Vaccine Tackles South Africa Variant

Moderna said Tuesday its Covid-19 vaccine was more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose.

News for Moderna Stock (MRNA)